知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

10 records (took 0.019 seconds)

    High citrate dialysate and uses thereof
    1.
    发明授权
    High citrate dialysate and uses thereof 有权
    高柠檬酸盐透析液及其用途

    公开(公告)号：US08864699B2

    公开(公告)日：2014-10-21

    申请号：US12973598

    申请日：2010-12-20

    Applicant: Robin Callan ,  James J. Cole

    Inventor： Robin Callan ,  James J. Cole

    IPC: A61M37/00 ,  A61M1/36 ,  A61K33/10 ,  A61K31/19 ,  A61M1/16 ,  A61K33/14 ,  A61K31/191

    CPC classification number: A61M1/1654 ,  A61K31/19 ,  A61K31/191 ,  A61K33/10 ,  A61K33/14 ,  A61M1/3672 ,  A61M1/3675 ,  A61M2202/0413 ,  A61K2300/00

    Abstract: The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-dialysis serum HCO3 level is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-dialysis serum HCO3>23 mEq/L (lower limit of normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCO3 normalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout. In these patients, the initial average urea reduction ratio (URR) was 68.5±5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73±5.3% (p

    Abstract translation: 尿素清除方面的透析剂量在许多血液透析患者中​​是微不足道的，而通过透析前血清HCO3水平测定的代谢性酸中毒是常见的。 包含柠檬酸而不是乙酸作为酸化剂的透析液提供优异的性能。 含有柠檬酸盐的透析液仅用于22例血液透析患者。 最初，22例患者中只有8例血液中HCO3> 23mEq / L（正常值下限），然而，使用柠檬酸盐透析液透析12周后，血清HCO3在15例患者（p = 0.0001，卡方）。 在19例患者中透析变量保持不变，他们也使用和重复使用相同的透析器模型。 在这些患者中，初始平均尿素减少率（URR）为68.5±5.9％，用本文公开的柠檬酸盐透析液处理后，该比例增加至73±5.3％（p <0.03）。 使用Daugirdas II公式计算的SpKt / V也从1.23±0.19增加到1.34±0.2（p = 0.01）。 这种增加的尿素清除可能是柠檬酸盐维持透析膜通畅的抗凝血性能的结果。 透析前血清HCO3的增加可能代表来自透析液的增加的递送和柠檬酸的产生。

    High citrate dialysate and uses thereof
    7.
    发明授权
    High citrate dialysate and uses thereof 有权
    高柠檬酸盐透析液及其用途

    公开(公告)号：US07862530B2

    公开(公告)日：2011-01-04

    申请号：US10984374

    申请日：2004-11-08

    Applicant: Robin Callan ,  James J. Cole

    Inventor： Robin Callan ,  James J. Cole

    IPC: A61M37/00 ,  B01D11/00 ,  B01D61/00 ,  C02F1/44

    CPC classification number: A61M1/1654 ,  A61K31/19 ,  A61K31/191 ,  A61K33/10 ,  A61K33/14 ,  A61M1/3672 ,  A61M1/3675 ,  A61M2202/0413 ,  A61K2300/00

    Abstract: The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-dialysis serum HCO3 level is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-dialysis serum HCO3>23 mEq/L (lower limit of normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCO3 normalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout. In these patients, the initial average urea reduction ratio (URR) was 68.5±5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73±5.3% (p

    Abstract translation: 尿素清除方面的透析剂量在许多血液透析患者中​​是微不足道的，而通过透析前血清HCO3水平测定的代谢性酸中毒是常见的。 包含柠檬酸而不是乙酸作为酸化剂的透析液提供优异的性能。 含有柠檬酸盐的透析液仅用于22例血液透析患者。 最初，22例患者中只有8例血液中HCO3> 23mEq / L（正常值下限），然而，使用柠檬酸盐透析液透析12周后，血清HCO3在15例患者（p = 0.0001，卡方）。 在19例患者中透析变量保持不变，他们也使用和重复使用相同的透析器模型。 在这些患者中，初始平均尿素减少率（URR）为68.5±5.9％，用本文公开的柠檬酸盐透析液处理后，该比例增加至73±5.3％（p <0.03）。 使用Daugirdas II公式计算的SpKt / V也从1.23±0.19增加到1.34±0.2（p = 0.01）。 这种增加的尿素清除可能是柠檬酸盐维持透析膜通畅的抗凝血性能的结果。 透析前血清HCO3的增加可能代表来自透析液的增加的递送和柠檬酸的产生。

    High citrate dialysate and uses thereof
    10.
    发明申请
    High citrate dialysate and uses thereof 有权
    高柠檬酸盐透析液及其用途

    公开(公告)号：US20050119598A1

    公开(公告)日：2005-06-02

    申请号：US10984374

    申请日：2004-11-08

    Applicant: Robin Callan ,  James Cole

    Inventor： Robin Callan ,  James Cole

    IPC: A61K31/19 ,  A61K31/191 ,  A61K33/10 ,  A61K33/14 ,  A61M1/16 ,  A61M1/36 ,  A61M37/00 ,  C02F1/44

    CPC classification number: A61M1/1654 ,  A61K31/19 ,  A61K31/191 ,  A61K33/10 ,  A61K33/14 ,  A61M1/3672 ,  A61M1/3675 ,  A61M2202/0413 ,  A61K2300/00

    Abstract: The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-dialysis serum HCO3 level is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-dialysis serum HCO3>23 mEq/L (lower limit of normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCO3 normalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout. In these patients, the initial average urea reduction ratio (URR) was 68.5±5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73±5.3% (p

    Abstract translation: 在尿素清除方面的透析剂量在许多血液透析患者中​​是微不足道的，并且通过透析前血清HCO 3水平测定的代谢性酸中毒是常见的。 包含柠檬酸而不是乙酸作为酸化剂的透析液提供优异的性能。 含有柠檬酸盐的透析液仅用于22例血液透析患者。 最初，22例患者中只有8例具有透析前血清HCO 3 / 23mEq / L（正常下限），然而，使用含柠檬酸盐透析液透析12周后， 15例患者血清HCO 3标准化（p = 0.0001，卡方）。 在19例患者中透析变量保持不变，他们也使用和重复使用相同的透析器模型。 在这些患者中，初始平均尿素减少率（URR）为68.5±5.9％，用本文公开的柠檬酸盐透析液处理后，该比例增加至73±5.3％（p <0.03）。 使用Daugirdas II公式计算的SpKt / V也从1.23±0.19增加到1.34±0.2（p = 0.01）。 这种增加的尿素清除可能是柠檬酸盐维持透析膜通畅的抗凝血性能的结果。 透析前血清HCO 3 <3>的增加可能代表来自透析液的增加的递送和来自柠檬酸的产生。

Patent Agency Ranking